Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "Fangsheng Jianmeng"), has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its chemical generic drug research project, Relugolix tablets, which is a GnRH receptor antagonist used for the treatment of advanced prostate cancer [1]. Group 1 - Fangsheng Jianmeng has obtained regulatory approval for the clinical trial of Relugolix tablets [1]. - Relugolix is indicated for the treatment of adult patients with advanced prostate cancer [1].

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary has received approval for a clinical trial of a new drug aimed at treating advanced prostate cancer, indicating progress in its drug development pipeline [1] Group 1: Company Developments - Fangsheng Pharmaceutical announced on October 15 that its wholly-owned subsidiary, Fangsheng Jianmeng, has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for the drug RuLuGoli Tablets [1] - RuLuGoli Tablets are classified as gonadotropin-releasing hormone (GnRH) receptor antagonists, specifically designed for the treatment of adult advanced prostate cancer [1]

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary has received approval for the clinical trial of a new drug, Relugolix, which is a GnRH receptor antagonist for treating advanced prostate cancer [1] Group 1: Drug Development and Approval - The clinical trial approval notification for Relugolix was issued by the National Medical Products Administration [1] - The total investment in the drug development project has reached approximately 3.89 million yuan (around 0.6 million USD) as of the announcement date [1] Group 2: Market Potential - The global sales of Relugolix in 2023 amounted to 300 million USD, reflecting a year-on-year growth rate of 58.6% [1] - The drug development process, from research to clinical trial approval and production, is lengthy and involves multiple stages, which can be affected by various uncertainties [1]

Core Viewpoint - Fangsheng Pharmaceutical's stock has shown a significant increase in price and trading activity, indicating positive market sentiment and potential investment interest [1][2]. Group 1: Stock Performance - Fangsheng Pharmaceutical's stock price increased by 21.18% year-to-date, with a 1.34% rise in the last five trading days, 7.44% in the last 20 days, and 18.57% in the last 60 days [2]. - As of October 14, the stock was trading at 12.13 CNY per share, with a market capitalization of 5.326 billion CNY [1]. Group 2: Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported revenue of 834 million CNY, a year-on-year decrease of 8.35%, while net profit attributable to shareholders was 169 million CNY, reflecting a year-on-year increase of 23.67% [2]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased to 33,100, with an average of 13,245 circulating shares per shareholder, a decrease of 0.36% from the previous period [2]. - The company has distributed a total of 689 million CNY in dividends since its A-share listing, with 444 million CNY distributed over the last three years [3]. Group 4: Institutional Holdings - As of June 30, 2025, major institutional shareholders include ICBC Medical Health Stock, holding 5.3997 million shares, and Rongtong Health Industry Flexible Allocation Mixed A/B, which increased its holdings by 500,000 shares to 5 million [3].

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. has signed a contract with Liao Ning Yifan Pharmaceutical Co., Ltd. to acquire the marketing authorization for "Compound Dexamethasone Cream," which includes ownership of the drug formula, production process, technical secrets, and related patents and data [2][11]. Group 1: Transaction Overview - The company has entered into a technology transfer contract to acquire the marketing authorization for "Compound Dexamethasone Cream" [2]. - The transaction does not constitute a related party transaction or a major asset restructuring, and it is within the approval authority of the chairman, thus not requiring board or shareholder approval [2]. - The transfer fee is structured in three phases, with 30% payable within five working days of signing, another 30% upon completion of production site change, and 40% after receiving the approval notice from the drug review center [8]. Group 2: Market Situation - There are 103 companies in China that have obtained production licenses for "Compound Dexamethasone Cream" [3]. - The sales figures for the cream in physical pharmacies were 175 million yuan in the first half of 2025 and projected to reach 429 million yuan in 2024 [3]. - The global market sales for dexamethasone formulations were approximately $1.198 billion in 2022 and $1.203 billion in 2023 [3]. Group 3: Impact on the Company - The acquisition aligns with the company's strategy to become a health industry group focused on innovative traditional Chinese medicine, enhancing its product pipeline and potentially providing new profit growth points [11]. - The addition of this dermatological product category is expected to strengthen the company's market competitiveness and facilitate industry chain integration and expansion [11].

Group 1 - Changyuan Power reported a power generation of 2.742 billion kWh in September, a year-on-year decrease of 41.88% [1] - The cumulative power generation from January to September was 27.332 billion kWh, down 8.24% year-on-year [1] - Huanyu Electronics achieved a consolidated revenue of 5.96 billion yuan in September, a year-on-year increase of 0.1% [1][2] Group 2 - Zhonghuan Environmental announced a change in controlling shareholder, with 27.5% of shares being transferred for a total consideration of 598 million yuan [2] - *ST Songfa's subsidiary signed contracts for the construction of 6 VLCCs, with a total contract value of approximately 600-900 million USD [1][3] - Suzhou Xinchen Technology's subsidiary plans to acquire 55% of Kunyu Lancheng for 74.25 million yuan [3] Group 3 - Guiguan Power reported a cumulative power generation of 31.848 billion kWh for the first three quarters, a year-on-year increase of 14.89% [4] - Jincheng Pharmaceutical's subsidiary received approval for the market launch of a raw material drug [4] - Shandong Steel expects a net profit of approximately 140 million yuan for the first three quarters, an increase of about 21.96 million yuan year-on-year [4][5] Group 4 - Xiangjia Co. reported sales revenue of 96.6186 million yuan from live poultry in September, with a sales price of 12.10 yuan/kg [6] - Aonong Bio's pig sales volume in September increased by 12.2% year-on-year, with a total of 164,400 pigs sold [7] - Mingtai Aluminum's aluminum plate and foil sales reached 1.1747 million tons in the first three quarters [8] Group 5 - Guangzhou Port expects to complete a container throughput of 2.051 million TEUs in September, a year-on-year decrease of 0.8% [11] - Jiangsu Sop plans to conduct a month-long maintenance on several production units starting October 10 [12] - Baike Bio received approval for a clinical trial of a combined vaccine for infants [13] Group 6 - Yutong Bus reported a 25.55% year-on-year increase in bus sales in September, totaling 4,756 units [16] - Shanghai Rural Commercial Bank's vice chairman and president's qualifications were approved [19] - Huayu Pharmaceutical's product received market approval in four countries [20] Group 7 - Longan Automobile reported a 24.92% year-on-year increase in vehicle sales in September, totaling 266,300 units [38] - Chip Origin expects a third-quarter revenue of 1.284 billion yuan, a year-on-year increase of 78.77% [39] - Bomaike signed a contract for an offshore floating production storage and offloading vessel project, with a contract value of approximately 190-240 million USD [40]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has signed a technology transfer contract with Yifan Pharmaceutical to acquire the marketing authorization for "Compound Dexamethasone Acetate Cream," which includes ownership of the drug prescription, production process, technical secrets, related patents, and technical data [1] Group 1: Strategic Development - The company aims to become a health industry group centered on innovative traditional Chinese medicine, continuously increasing R&D investment while also acquiring products with development potential to enrich its product pipeline [1] - The acquisition of the marketing authorization is aligned with the company's development strategy, facilitating industry chain integration and expansion, thereby enhancing market competitiveness [1] Group 2: Product Expansion - Following the acquisition, the company's dermatological product category will be effectively expanded, with the potential for new profit growth through brand empowerment within the group [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has signed a technology transfer agreement with Yifan Pharmaceutical to acquire the marketing authorization for "Compound Dexamethasone Acetate Cream," which includes ownership of the drug's prescription, production process, technical secrets, and related patents and data [1] Group 1: Strategic Development - The company aims to become a health industry group centered on innovative traditional Chinese medicine, continuously increasing R&D investment while also acquiring products with development potential to enrich its product pipeline [1] - The acquisition of the marketing authorization will effectively expand the company's dermatological drug category, potentially providing new profit growth points through brand empowerment [1] Group 2: Market Positioning - This acquisition aligns with the company's development strategy, facilitating industry chain integration and expansion, thereby enhancing the company's market competitiveness [1]

湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 9 月 30 日，公司与亿帆药业签订了《技术转让（技术秘密）合同》， 决定受让其"复方醋酸地塞米松乳膏"药品上市许可（包括但不限于药品处方、生产工 艺、技术秘密、与标的品种相关的专利、技术资料等数据的所有权）； 本次交易不构成关联交易，亦未构成重大资产重组；交易实施不存在重大法律 障碍，根据《公司章程》规定，该事项在董事长审批权限内，无需经董事会、股东会审 议批准； 风险提示：本次受让药品上市许可，尚需办理药品上市许可持有人变更手续， 办理完成时间具有不确定性，预计不会对公司当期经营产生重大影响；药品未来的具体 销售情况可能受到市场环境变化等因素影响，具有不确定性，敬请广大投资者谨慎决策， 注意防范投资风险 证券代码：603998 证券简称：方盛制药 公告编号：2025-083 湖南方盛制药股份有限公司 关于受让药品上市许可的公告 一、交易概述 1、标 ...

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced on October 9 that it signed a technology transfer contract with Yifan Pharmaceutical on September 30, acquiring the marketing authorization for "Compound Dexamethasone Acetate Cream" [1] Group 1 - The acquired drug is indicated for localized pruritus, neurodermatitis, contact dermatitis, seborrheic dermatitis, and chronic eczema [1]